




*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

17w



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

KENICHIRO HASUMI

Serial No.: 10/783,259

Filed: February 20, 2004

Art Unit: 1648

:  
:  
:  
:  
:  
:  
:  
:  
:

HUMAN LYMPHOCYTE VACCINE  
ADJUVANT

Attorney Docket No.: 358690-00005-1

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mail Stop AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Enclosed is the captioned Supplemental Information Disclosure Statement which presents art which was first brought to Applicant's attorney's attention in an International Search Report dated August 29, 2005, issued in the PCT patent application directed toward a human lymphocyte vaccine adjuvant. A copy of the Search Report along with the prior art citation and a completed form PTO/SB/08B (08-03) is enclosed.

This Statement is filed solely for the purpose of complying with the pertinent rules of the Office and is not intended to be a substitute for an independent evaluation by the examiner of the art cited or an independent search by the examiner, and no representation of any nature is made or intended by the filing of this Statement.


In addition to the art cited on form PTO/SB/08B, Applicant and/or his attorneys may have been exposed to or considered additional art relating to the general class of the subject matter of the invention. However, if in fact such exposure or consideration has occurred, to the best of their recall or judgment, none of such art is prior art which is more relevant than the art cited.

Respectfully submitted,

Eric A. Lerner  
Registration Number 46,054  
Eckert Seamans Cherin & Mellott, LLC  
600 Grant Street, 44<sup>th</sup> Floor  
Pittsburgh, Pennsylvania 15219  
Telephone: 412-566-6085  
Attorney for Applicant

October 20, 2005

Date



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

### Complete if Known

Application Number	10/783,259
Filing Date	FEBRUARY 20, 2004
First Named Inventor	KENICHIRO HASUMI
Art Unit	1648
Examiner Name	Not yet assigned
Attorney Docket Number	358690-00005-1

Sheet 1 of 1

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		G.T. BRICE et al. "Development of an Animal Model for Autotransfusion Therapy: In Vitro Characterization and Analysis of Anti-CD3/CD28 Expanded Cells" Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 19:210-220, 1998, Lippincott Williams & Wilkins, Philadelphia, USA.	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.